TMOD-03. GAINING A MECHANISTIC UNDERSTANDING OF THERAPY EVASION FROM DUAL MAPK PATHWAY INHIBITION IN A SYNGENEIC BRAFV600E MUTANT CDKN2A DELETED MOUSE MODEL TO PREEMPT RESISTANCE IN PATIENTS WITH BRAFV600E MUTANT PEDIATRIC GLIOMA

Pediatric patients with gliomas expressing the constitutively active BRAF(V600E)-mutant kinase are candidates for clinical trials for small molecule inhibitors specific for BRAF(V600E) (BRAFi) and MEK (MEKi) (Grossauer et al; Oncotarget 2016, 15:75839). Clinical results from combined BRAF and MEK in...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Main Authors: Wang, Wei, Grossauer, Stefan, Koeck, Katharina, Simonds, Erin, Lu, Edbert, Bergers, Gabriele, Weiss, William, Petritsch, Claudia
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2019
Assuntos:
Pediatric Brain Tumor Models
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6477238/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz036.242
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares